Tag: PTBI

Blue Horseshoe Stocks: ACRX, DSCO & More

Tesla Motors, Inc. TSLA – Options

Yesterday, those of our readers following our recent coverage of TSLA were once again presented with opportunities coming out of the 05/22 $230-240 Calls that we’ve been monitoring since Friday. TSLA registered a higher high and a higher low for the fifth consecutive session, topping out at 248.30. As a result, the total possible gains on our initial calls were pushed even further into the green, so we wanted to provide an update on those figures:

$230 Calls  – Friday’s Low: 6.85 – Yesterday’s High: 17.95 – Max Gain: 162%

$232.50 Calls  – Friday’s Low: 5.32 – Yesterday’s High: 16.90 – Max Gain: 217%

$235 Calls  – Friday’s Low: 5.96 – Yesterday’s High: 13.95 – Max Gain: 134%

$237.50 Calls  – Friday’s Low: 3.16 – Yesterday’s High: 12.00  – Max Gain: 280%

$240 Calls  – Friday’s Low: 3.84 – Yesterday’s High: 10.50 – Max Gain: 173%

These moves are a perfect example of what draws us to options trading; with just a 6% increase in TSLA stock, we’ve witnessed huge gains across the board in the options chain. These contracts don’t expire until next Friday, so we’ll keep our fingers on TSLA’s pulse until that time.

AcelRx Pharmaceuticals, Inc. ACRX

Popping up on our scanner this morning is a play that has both an interesting chart as well as a blockbuster PR out today that is leading to a gap-up in premarket trading (3.30-3.80’s).

We’re catching the stock as it comes up off of a relative bottom, and as we point out on the snapshot below, there are several attractive features of the current ACRX chart.

Couple that with this morning’s revelation of a contract the company has struck with the US Dept. of Defense, and ACRX becomes instantly worthy of our attention as the week draws to a close.

Discovery Laboratories, Inc. DSCO

Speaking of pharma stocks with fresh news, DCSO is also cropping up on our scanner this morning. Like the aforementioned play, this morning/s PR is resulting in a gap-up, and we’ll want to have our eyes peeled for potential advantageous activity on the chart once the session commences.

According to the release, Phase II testing of its AEROSURF® product has yielded “encouraging safety and physiological data suggest that aerosolized KL4 surfactant can be delivered to the lung of premature infants with respiratory distress syndrome”

Extended Watchlist:
PTBI, CYRN, BAA, CDTI, WOGI

Blue Horseshoe Stocks: GEVO News, PTBI Review & More

PlasmaTech Biopharmaceuticals, Inc. PTBI

In Tuesday morning’s premarket report, we expressed our interest in PTBI based on some press, and the look of the chart. We expected to see a chance for a nice gain, but what followed has been much more impressive.

PTBI has become a multi-day runner; Tuesday’s session brought a move from 4.33-7.77, an intraday gain of 79%

Yesterday, the company came out with news of a new acquisition in the morning, and that certainly added fuel to the fire. After a gap-up we witnessed an early run from 8.71-11.15 (+28%). That high represented a two-day increase of 157% over our observed low of 4.33, and was followed by some consolidation in the afternoon leading to a close at 8.60.

The company published another press release post-market divulging details of a forthcoming private placement (Link Below), that is untraded-upon. Thus, PTBI is gapping up once again today, so we will be wary of the possibility for more price action similar to what we’ve seen so far.

Extreme Networks, Inc. EXTR

We’re going to put EXTR on our radars this week as a stock that was sent through the ringer after an analyst downgrade early last month, causing a big gap-down on the chart.

You can see it plainly on the snapshot we’ve included below. In addition, we can identify a couple of bullish indicators staring us in the face; the RSI is coming off of being oversold, while the MACD is upturned and showing divergence. The stock has been making higher highs and higher lows for two sessions running, and we’ll look for that to continue.

Gevo, Inc. GEVO

We also want to pay attention to GEVO after an interesting PR this morning that highlights an agreement with Alaska Airlines has sent the stock cruising to three-month highs in the premarket.

The chance for a dip-and-rip style play could present itself on the rebound after the profit-takers come out of the woodwork early in today’s session. For us to remain interested in GEVO, the stock will need to maintain support at or above its 50DMA of 3.23 on any pullback.

Extended Watchlist:
TSLA, BABA, QLTY, FRO, SYMX, AXPW

Blue Horseshoe Stocks: PTBI Makes Huge Run & Extended Watchlist

PlasmaTech Biopharmaceuticals, Inc. PTBI

We were on top of PTBI in yesterday morning’s premarket report, catching it off of our scanner after an interesting PR alluded to activist investor George Soros taking up a position in the company. We also identified the attractiveness of the chart, and went so far as to say: “we like its chances of making a nice run.” Our expectations were exceeded roundly, and we actually ended up seeing a terrific run!

From an early low of 4.33 the stock surged to an impressive daily high of 7.77, carving out a 79% intraday rip on the chart. For a NASDAQ-listed $4.00+ stock, that is an incredible single-session performance.

The stock is pushing to new highs here in the premarket, and has officially crossed over the 100%-gainer line in less than a 24-hour period.

Take a look at the video chart we’ve prepared outlining PTBI’s epic performance so far:

Today’s continued momentum can likely be attributed to another PR out this morning, this time referring to a new acquisition. We’d suggest our readers follow the link to that press, included below. We’ll be actively monitoring this stock as we cruise through this midweek.

Extended Watchlist:
FATE, BRDR, ICLD, PBR PWE, MGI